Malaria vaccines: facing unknowns

F1000Res. 2020 Apr 27:9:F1000 Faculty Rev-296. doi: 10.12688/f1000research.22143.1. eCollection 2020.

Abstract

Much of the gain in malaria control, in terms of regional achievements in restricting geographical spread and reducing malaria cases and deaths, can be attributed to large-scale deployment of antimalarial drugs, insecticide-treated bed nets, and early diagnostics. However, despite impressive progress, control efforts have stalled because of logistics, unsustainable delivery, or short-term effectiveness of existing interventions or a combination of these reasons. A highly efficacious malaria vaccine as an additional tool would go a long way, but success in the development of this important intervention remains elusive. Moreover, most of the vaccine candidate antigens that were investigated in early-stage clinical trials, selected partly because of their immunogenicity and abundance during natural malaria infection, were polymorphic or structurally complex or both. Likewise, we have a limited understanding of immune mechanisms that confer protection. We reflect on some considerable technological and scientific progress that has been achieved and the lessons learned.

Keywords: Plasmodium; malaria; vaccine.

Publication types

  • Review

MeSH terms

  • Antigens, Protozoan / immunology
  • Humans
  • Malaria / immunology
  • Malaria / prevention & control*
  • Malaria Vaccines*

Substances

  • Antigens, Protozoan
  • Malaria Vaccines

Grants and funding

The author(s) declared that no grants were involved in supporting this work.